FDA Issues Bispecific Antibody Development Guidance
The agency provides recommendations for the development of bispecific antibody development programs that include regulatory, quality, nonclinical, and clinical considerations.
FDA published guidance on April 18, 2019 giving recommendations for the development of bispecific antibody development programs. General regulatory and scientific considerations for bispecific antibodies are discussed. The agency states in the guidance that the development of a specific individual, bispecific antibody development program should be discussed with FDA. The guidance addresses regulatory, quality, nonclinical, and clinical considerations but does not discuss multitarget therapies that are combinations of monoclonal antibodies or are antibody cocktails or polyclonal antibodies.
According to FDA, “bispecific antibodies can target multiple disease-modifying molecules with one drug, with possible advantages over combination therapy or the use of antibody mixtures.” Developing bispecific antibodies can be a challenge, however. The guidance clarifies which type of data are necessary to support the approval of bispecific antibodies.
Source: FDA
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
